Over a decade ago, a group of researchers led by two diabetes experts, Richard DiMarchi and Matthias Tschöp, published a landmark paper in mice that suggested a new way to treat obesity and diabetes.
The drug in the study activated two gut hormone receptors — the now famous GLP-1 and its less appreciated sibling GIP. Eli Lilly went on to use that approach to develop tirzepatide, the diabetes and weight loss medicine Mounjaro and Zepbound.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.